# Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

> **NCT06670222** · PHASE1 · RECRUITING · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 24 (estimated)

## Conditions studied

- Low-risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** Arsenic Trioxide (ATO)

## Key facts

- **NCT ID:** NCT06670222
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670222, "Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06670222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*